Anne M. Rompalo, MD

CRS:

JHU

Role:

Investigators

Position:

HPTN Site Leader

Email:

arompalo@jhmi.edu

Anne M. Rompalo, M.D., Sc.M.  Dr. Rompalo is a Professor of Medicine and Gynecology at the Johns Hopkins University School of Medicine (JHUSOM), with joint appointments in Epidemiology, International Health and Population, Family and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health.  She is Medical Director of the CDC-sponsored Sexually Transmitted Diseases (STD)/HIV Prevention Training Center at Johns Hopkins (PTC), and has previously been Acting Medical Director of the Baltimore City Health Departments STD Clinics and Medical Director of the Office of Population Affairs Male Training Center.  She has over 15 years of experience as the Medical Director of the STD/HIV PTC, and has been a key investigator on several studies focused on the natural history of HIV among women including the HERS (HIV Epidemiology Research Study) and HIV prevention among U.S. women at high risk for infection, HPTN 064 trial. 

  • Investigator of Record, HPTN 064
  • Investigator of Record, HPTN 083

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

Read More